Cbay stock forecast.

CBAY stock showed promising performance on November 8, 2023, according to data from CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc had a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.

Cbay stock forecast. Things To Know About Cbay stock forecast.

About the CymaBay Therapeutics, Inc. stock forecast. As of 2023 November 25, Saturday current price of CBAY stock is 19.100$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Cymabay Therapeutics stock price as been showing a rising tendency so we believe that similar …CBAY stock performances on November 6, 2023, are expected to be positive based on the information provided. According to data from CNN Money, the 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of $22.50, with a high estimate of $33.00 and a low estimate of $19.00.Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...View the latest CymaBay Therapeutics Inc. (CBAY) stock price, news, historical charts, analyst ratings and financial information from WSJ.Newark, California-based CymaBay Therapeutics (CBAY) was approved for uplisting to the Nasdaq in June 2014, with stock initially trading at a value of $19. Across the next 9 years they have been ...

AC Immune S.A. analyst ratings, historical stock prices, earnings estimates & actuals. ACIU updated stock price target summary.

Coterra Energy Inc () Stock Market info Recommendations: Buy or sell Coterra Energy stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Coterra Energy share forecasts, stock quote and buy / sell signals below.According to present data Coterra Energy's CTRA shares and potentially its market environment have …Find real-time VSTM - Verastem Inc stock quotes, company profile, news and forecasts from CNN Business.

According to . 9 Wall Street analysts that have issued a 1 year CBAY price target, the average CBAY price target is $24.56, with the highest CBAY stock price forecast at $34.00 and the lowest CBAY stock price forecast at $15.00. The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its historical Stock Score levels. CBAY Stock Shows Promising Performance: Analysts Predict 38.63% Increase CBAY stock had a promising performance on November 6, 2023, based on the information provided by CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Cymabay Therapeutics Inc (CBAY) has traded red over the past five days. The stock hit a weekly high of 16.87 this Thursday, 11/02/23. The 5-day price performance for the stock is 8.04%, and 17.06% over 30 days. With these gigs, the year-to-date price performance is 161.56%.

We can readily understand why investors are attracted to unprofitable companies. Indeed, CymaBay Therapeutics (NASDAQ:CBAY) stock is up 154% in the last year, providing strong gains for shareholders.

Dec 1, 2023 · CBAY is a biopharmaceutical company that develops and commercializes new medicines for important human diseases. The stock price, earnings, news, and research reports of CBAY are available on Zacks. See the latest Zacks Rank, Style Scores, EPS Surprise, and more for CBAY.

Dec 1, 2023 · CBAY Earnings Date and Information. CymaBay Therapeutics last posted its earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02. See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. CBAY Stock Price Quote | Morningstar...Stem, Inc. (NYSE:STEM) released its earnings results on Thursday, November, 2nd. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm had revenue of $133.74 million for the quarter, compared to the consensus estimate of $182.46 million.Stock Price Forecast. The 14 analysts offering 12-month price forecasts for International Business Machines Corp have a median target of 145.00, with a high estimate of 179.00 and a low estimate ...A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing.

CPG Stock 12 Months Forecast. Based on 10 Wall Street analysts offering 12 month price targets for Crescent Point Energy in the last 3 months. The average price target is C$14.80 with a high forecast of C$19.00 and a low forecast of C$13.00. The average price target represents a 53.50% change from the last price of C$9.64.CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline ...28/12/2022 ... Impact of many factors on the stock prices makes the stock prediction a difficult and highly complicated task.Insiders who bought CymaBay Therapeutics, Inc. (NASDAQ:CBAY) stock lover the last 12 months are probably not as affected by last week’s 11% loss.After accounting for the recent loss, the US$161k ...(See CBAY stock forecast) Cerevel Therapeutics . The next Edelman choice is Cerevel, a company established in 2018 that specializes in the field of neuroscience. Cerevel’s focus is on the ...

CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates. by Zacks Equity Research Published on November 10,2021. CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue ...All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...

Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40. Analyst Forecast. According to 12 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is $22.64, which is an increase of 18.35% from the latest price.The Cymabay Therapeutics stock forecast is 22.75112265303 USD for 2024 November 25, Monday; and 52.714 USD for 2028 November 25, Saturday with technical analysis. Cymabay Therapeutics (CBAY) stock price prediction is 22.75112265303 USD.Coterra Energy Inc () Stock Market info Recommendations: Buy or sell Coterra Energy stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Coterra Energy share forecasts, stock quote and buy / sell signals below.According to present data Coterra Energy's CTRA shares and potentially its market environment have …Discover historical prices for CBAY stock on Yahoo Finance. View daily, weekly or monthly format back to when CymaBay Therapeutics, Inc. stock was issued. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Research CymaBay Therapeutics' (Nasdaq:CBAY) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more. ... Revenue is forecast to grow 61.55% per year. Risk Analysis. Currently unprofitable and not forecast to become profitable over the next 3 years.Analyst projections state that BYND is forecast to be at a low of $3.00 and a high of $9.00. In order for the stock price to hit the forecast high, the stock would need to plunge -39.32% from its current level, while the stock would need to crash 53.56% from its current level to reach the projected low. Beyond Meat Inc (BYND) estimates and ...Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing. CBAY is pre-revenue, given its pre-clinical status. It recorded $30mm in cash on the balance sheet last report , with an additional $122mm in marketable securities. Subsequently, it had $150mm in ...

The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low.

He kept his outperform rating on CBAY stock and raised his price target to 20 from 18. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This ...

Jun 30, 2023 · CBAY Stock Forecast: Positive Outlook and Analyst Consensus for CymaBay Therapeutics Inc. CBAY stock has been performing well in recent months, with positive forecasts from analysts. On June 30, 2023, the 10 analysts offering 12-month price forecasts for CBAY had a median target of $15.00, indicating a potential increase of 35.14% from the last ... Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40.Is Cymabay Therapeutics (NASDAQ:CBAY) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...Nov 30, 2023 · CBAY Signals & Forecast. Mostly positive signals in the chart today. The Cymabay Therapeutics Inc stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.Stock Price Forecast. The 22 analysts offering 12-month price forecasts for Thermo Fisher Scientific Inc have a median target of 519.50, with a high estimate of 600.00 and a low estimate of 435.00 ...CDTX Stock 12 Months Forecast. Based on 1 Wall Street analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 679.22% change from the last price of $0.77.

Sep 8, 2023 · He kept his outperform rating on CBAY stock and raised his price target to 20 from 18. Notably, CymaBay stock has a best-possible Relative Strength Rating of 99, according to IBD Digital. This ... Nov 27, 2023 · See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Instantly CBAY has been showing red trend so far today with a performance of -1.24% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 186.68% year-to-date, but still down -3.67% over the …Instagram:https://instagram. taxation of currency tradingis american hartford gold legitimategroundfloor competitorsfsvlx stock Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather. sqmstockmortgage companies in virginia September 8, 2023 at 1:12 PM · 3 min read. Shares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it announced positive top-line results from its late ... how to buy elon coin Nov 27, 2023 · See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Shares of CymaBay Therapeutics ( CBAY -1.16%) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday. The continued momentum is a result ...The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its …